NCT06046040View on ClinicalTrials.gov

TmPSMA-02 in mCRPC

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

8

Participants

Timeline

Start Date

January 31, 2024

Primary Completion Date

January 31, 2027

Study Completion Date

January 31, 2042

Conditions
Metastatic Castrate-Resistant Prostate Cancer (mCRPC)
Interventions
DRUG

TmPSMA-02 CAR T Cells

TmPSMA-02 CAR T cells: autologous T cells transduced with a lentiviral vector to express an anti-PSMA CAR containing a humanized J591-derived scFv and CD2 co-stimulatory domain, and dually armored with a TGFβRDN and PD1.CD28 switch receptor.

Trial Locations (1)

19104

Abramson Cancer Center of the University of Pennsylvania, Philadelphia

All Listed Sponsors
collaborator

Prostate Cancer Foundation

OTHER

lead

University of Pennsylvania

OTHER

NCT06046040 - TmPSMA-02 in mCRPC | Biotech Hunter | Biotech Hunter